Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Historically, epidermolysis bullosa subtypes have been classified according to skin morphology. Treatment Exogenous agents contributing to impairment of wound healing include glucocorticoids and penicillamine.
Optimizing wound healing in patients with epidermolysis bullosa (EB) involves controlling all of these factors. Patients with Herlitz junctional epidermolysis bullosa heal slowly, which may be because of a defect in laminin 5 (a protein involved intimately in keratinocyte adhesion and migration). Statistics Over the past 15-20 years, 13 major genes responsible for the majority of cases of EB have been identified.
The genetic errors in EB result in defects in the proteins that adhere the epidermis to the dermis. Major research Stem Cell Transplant for Epidermolysis Bullosa. Characteristics of Patients With Dystrophic Epidermolysis Bullosa. Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa. Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care.